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A B S T R A C T
Purpose: We aimed to investigate the effects of levetiracetam on oxidative stress which is one of the new
antiepileptic drugs in epileptic patients.
Methods: The study consisted of 21 patients with cryptogenic partial epilepsy. We determined the
urinary 15F-2t-isoprostane levels of the 30 patients which is a marker of oxidative stress. Morning urine
samples were collected from the patients before beginning LEV and after 3 months treatment. Of these
patients 9were excluded from the study that had seizure history in the last 1month. Urinary levels of 15-
F2t-isoprostane determined by ELISA initially and after 3 months treatment for each patient.
Results: Mean age of the 21 patients was 29.6, of these 11were females and 10males. Mean urinary 15F-
2t-isoprostane level of the patients was 876  447 ng/mg Cr before the treatment of LEV. After 3 months
treatment the mean 15F-2t-isoprostane level of the patients was 1560  630. The patients had signiﬁcantly
higher levels of urinary 15F-2t-isoprostane when compared with initial levels (p = 0.025).
Conclusion: Our results showed the increase of urinary 15F-2t-isoprostane levels in epileptic patients
whom were treated with LEV which may indicate that LEV induces the oxidative stress in epileptic
patients.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Reactive oxygen species (ROS) are atoms or molecules with one
or more uncoupled electrons. ROS that occur during physiological
and pathological processes may damage cell compounds such as
lipid, protein, carbohydrate and DNA.1,2 Oxidative stress appears
when the production of ROS exceeds the removal capacity. The ROS
reactivity towards various molecular targets leads to oxidative
damage contributing to different human pathologies. Despite the
presence of the cell’s antioxidant defense system to counteract
oxidative damage from ROS, radical-related damage may play a
key role in the development of age-dependent diseases such as
cancer, arteriosclerosis, arthritis, neurodegenerative disorders and
other conditions.3 Some studies reported that free radicals may
play role in epilepsy.4,5 Generalized epilepsy may increase the
content of ROS and superoxide generation in the brain.6,7 Seizure-
induced lipid peroxidation has been reported by measuring* Corresponding author. Tel.: +90 2742271555.
E-mail address: scanbazkabay@yahoo.com (S.C. Kabay).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.07.010products such as thiobarbituric acid reactive substances8 and
F2-isoprostanes (F2-IsoPs) in rat brain tissue.9 In vivo detection of
free radicals is difﬁcult because of their very short lifetimes; other
parameters are used to measure oxidative stress. Considering that
lipid peroxidation is one of the most biological important free
radicals reactions,10 changes in lipid oxidation markers are
commonly used as indicators of oxidative stress in clinical
laboratory settings.11 Lipid peroxidation often appears in response
to oxidative stress, and a great variety of aldehydes are formed
when lipid hydroperoxides break down in biological systems. The
methods used detection of conjugated dienes, lipoperoxides, and
aldehydes are poorly reproducible and unreliable when carried out
in plasma because of the extreme reactivity and instability of the
species.12 Some researchers reported the production of a series of
prostaglandin F2-like compounds (F2-isoprostanes, F2-IsoPs),
which are formed in vitro and in vivo by free radical-catalyzed
peroxidation of phospholipid-bound arachidonic acid, a pathway
which is independent of the cyclooxygenase pathway.13,14
F2-isoprostanes are chemically stable prostaglandin isomers
consisted by free radical peroxidation of polyunsaturated fatty
acids, which are stored in tissues, circulate in plasma, and arevier Ltd. All rights reserved.
Fig. 1. Calculation of 15-F2t-IsoP levels according to standard in urinary levels of 15-
F2t-isoprostane kit.
Fig. 2. Calculation of creatinine according to standard in creatinine kit.
Fig. 3. Urinary 15-F2t-IsoP levels (ng/mg creatinine) before and after LEV of the
treatment. The mean difference is signiﬁcant at the .05 level.
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reliable markers of oxidative stress16 and can be used to evaluate
the oxidative stress in several of human pathologies. At the same
time, this is also the conclusion of a multilaboratory validation
study of the National Institute of Environmental Health Sciences.17
In some studies it was shown that valproic acid treatment in
epileptic children increased the urinary levels of 15-F2t-IsoPwhich
is amarker of oxidative stres.18 But there is not any study about the
effect of levetiracetam on levels of the urinary15-F2t-IsoP.
The aim of our study was to evaluate levels of urinary
isoprostane levels of epileptic patients, and then to determine
whether the treatment of levetiracetam might inﬂuence the
urinary isoprostane levels before and 3 months after therapy.
2. Materials and methods
All research procedures were approved by the University of
Dumlupinar Institutional Review Board and Eskisehir Osmangazi
University, Medical Faculty. Initially, the study consisted of 30
patients with cryptogenic partial epilepsy. Of these patients 9
were excluded from the study that had seizure history in the last 1
month. All patients were subjected to detailed clinical examina-
tion for evaluation of neurological status. Electroencephalogra-
phy (EEG) was conducted on all patients. MRI scan was done for
more detailed examination. All patients were suffering from
cryptogenic partial epilepsy. The patients who received levetir-
acetam (1000–3000 mg/day) for 3 months and who did not have
any clinical epileptic seizure during for the last 1 month were
included. Our exclusion criteria were abnormal neurological
examination, abnormal cerebral MRI scan, endocrinopathies,
liver, heart, kidney diseases, cancer, and any disease likely to
affect lipid metabolism, any inﬂammatory disease, and a body
mass index (BMI) > 25. Patients with past or concurrent diseases
which might affect the activity of antioxidant enzymes were
excluded from the study.Mean age of the 21 patientswhom lasted
the studywere 29.6, of these 11were females and 10males. Blood
samples were taken ﬁrst day of therapy. Urine samples were
collected from the participants beginning LEV and after 3 months
treatment. Blood samples were collected in serum separator
tubes, allowed to clot for 30 min, centrifuged at room temperature
for 15 min at 2000  g. The biochemicalmeasurementswere done
immediately, by using commercial available kits. The urine
samples were stored at 80 8C until analyzed. Routine blood
count and chemistry analysis and urinalysis were performed for
each patient, and those with abnormal results were excluded.
Urinary levels of 15-F2t-isoprostane determined by ELISA ﬁrst
and last day for each patient.
2.1. Urinary 15-F2t-IsoP immunoassay
Urinary 15-F2t-IsoP levels were analyzed using immunoassay
kits from Oxford Biomedical Research (Product number; EA 85).
Urine samples without additives added were thawed to room
temperature and diluted 1:2 using the dilution buffer provided
with the kit. Analysis was done according to the recommendations
of the manufacturer according to Fig. 1. Urinary levels are
dependent on the hydration status of the subject. To normalize
15-F2t-IsoP levels, urinary creatinine was assayed using a
creatinine kit from Oxford Biomedical Research (Product number;
CR 01) in Fig. 2. 15-F2t-IsoP concentration was expressed as nmol
15-F2t-IsoP/mmol creatinine.
2.2. Statistical analysis
All statistical analysis was performed with the computer
program ‘‘SPSS for Windows’’ (SPSS Inc; Release 11.5; September6, 2002). All of the data were expressed as means  SD. Differences
between groups were evaluated by one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison tests. The
signiﬁcance was tested at n.s. p > 0.05, p < 0.05, p < 0.01 and
p < 0.001.
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Initially, mean urinary 15F-2t-isoprostane levels of the patients
were 876  447 ng/mg Cr. After 3months treatment of LEV, themean
15F-2t-isoprostane levels of the patients were 1560  630. The
patients had signiﬁcantly higher levels of urinary 15F-2t-isoprostane
when compared with initial levels (p = 0.025) in Fig. 3.
4. Discussion
In this study, the oxidative status in epileptic patients before and
3 months after levetiracetam therapy was evaluated. The seizures
mediated brain injury is a dynamic process that includes multiple
factors such as genetic factors, the extent of glutamate-mediated
excitoxicity leading to disturbances in intracellular electrolyte
metabolism, mitochondrial dysfunction, oxidative stress and
changes in cytokines.19 Some studies reported an increase in
oxidative status in the brain of animals probably caused by
recurrent seizures.6,7 Free radical generation may induce seizure
activity by inactivation of glutamine synthase. Thus, oxidative
stress could exacerbate the etiology of epilepsy.6 There are some
conﬂict results in oxidative stress in epilepsy. Some authors
reported that increased lipid peroxidation of brain tissue was in
ferric chloride and kainate-induced epilepsy in experimental
studies.8,20 Patel et al. demonstrated that seizures induced the
increase in isofurans (novel products of lipid peroxidation)
formation and its correlation with changes in hippocampal pO2
and mitochondrial dysfunction.21 The conﬂicting results in oxida-
tive stress in epilepsy have not been exactly explained in the
literature. The variation of reported resultsmay result frompatients
included the study different forms of medication, type of seizure,
obesity. F2-Isops are desirable index of lipid peroxidation in vivo
because they are speciﬁc products of lipid peroxidation, detectable
in normal biological ﬂuids, modulated by antioxidant status; and
unaffected by dietary lipids and they increase dramatically in
models of oxidant injury.22 F2-IsoPs are not only most reliable
markers of oxidative stress16 but also have some biological effects
such as vasoconstriction with ischemia of the retina which account
for retinopathy of prematurity.23 Patel et al., showed that status
epilepticus results in the formation of lipid peroxidation end
products. Status epilepticus transiently decreases hippocampal
oxygen tension and F2-IsoP occurs during these hypoxic phase
whereas the formation of isofurans occurs when the tissue oxygen
levels return to normal. These data suggest that seizure-induced
changes in tissue oxygen levels andmitochondrial dysfunctionmay
differentially inﬂuence the formation of F2-IsoPs and IsoFs.21 Free
radicals and ROS may play role in epilepsy.4,5,24 Long-term use of
anticonvulsants has been shown to increase free radicals formation
and cause oxidative damage within neuronal cells.25 There are
several studies about the effect of valproic acid treatment on 15-
F2t-isoprostane levels.26,27,18 Tong et al. reported that the plasma
and liver levels of 15-F2t-isoprostane was increased in rats after
their treatment with VPA.26 Moreover, they reported VPA-induced
formation of 15-F2t-IsoP is associated with VPA glucronidation.27
Michoulas et al., demonstrate that treatment of childrenwith VPA is
associated with higher urinary levels of 15-F2t-IsoP, a marker of
oxidative stress.18 But there is no knowledge about effect of
levetiracetam treatment on urinary 15-F2t-isoprostane levels. The
report of the subcommittees of American Academy of Neurology
and American Epilepsy Society suggested that levetiracetam have
no serious adverse events and no known interactions with oral
contraceptives, warfarin, enzyme inducer and other antiepileptic
drugs.28 Our results showed the signiﬁcant higher levels of urinary
15F-2t-isoprostane levels in epileptic patients under LEV treatment
when compared with the initial levels. Considering the present
ﬁndings, it can be suggested that patients on LEV therapymay be atrisk of developing oxidative stress as shown by the remarkably high
urinary 15-F2t-isoprostane levels.
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